Clinical Trial Update: Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epoetin alfa to improve functional outcomes in anemic, critically ill trauma patients was terminated; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• Epogen (epoetin alfa)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia | Phase 2 | Status: TERMINATED | Results posted: 2009-12-22